Core Insights - Cryoport, Inc. reported a 9% year-over-year increase in Life Sciences Services revenue for Q3 2024, with BioStorage/BioServices revenue rising by 12% [1][2] - The company supported a record total of 691 global clinical trials as of September 30, 2024, marking a net increase of 21 trials from the previous year [1][9] - Cryoport reaffirmed its full-year 2024 revenue guidance of $225 million to $235 million, anticipating continued growth in services despite ongoing softness in product sales [3][20] Financial Performance - Total revenue for Q3 2024 was $56.7 million, a slight increase of 1% compared to $56.2 million in Q3 2023 [14] - Life Sciences Services revenue for Q3 2024 was $39.3 million, up 9% year-over-year, while Life Sciences Products revenue decreased by 13.7% to $17.4 million [14][15] - For the first nine months of 2024, total revenue was $168.9 million, down from $176.0 million in the same period of 2023 [14] Gross Margin and Operating Costs - The total gross margin improved to 44.8% in Q3 2024 from 43.2% in Q3 2023, with Life Sciences Services gross margin at 46.0% [15] - Operating costs and expenses for Q3 2024 were $41.8 million, slightly higher than $41.2 million in Q3 2023 [16] Net Income and Adjusted EBITDA - Cryoport reported a net income of $0.8 million for Q3 2024, a significant improvement from a net loss of $13.3 million in Q3 2023 [17] - Adjusted EBITDA for Q3 2024 was a negative $2.4 million, an improvement from a negative $3.1 million in Q3 2023 [18] Cash Position and Debt Management - As of September 30, 2024, Cryoport held $272.7 million in cash, cash equivalents, and short-term investments [18] - The company announced a repurchase program for up to $200 million of its common stock and/or convertible senior notes, with $175 million in convertible senior notes repurchased during Q3 2024 [18] Market Position and Future Outlook - Cryoport is strategically positioned to leverage anticipated long-term growth in the Life Sciences and Cell & Gene Therapy markets through its integrated supply chain solutions [5] - The company plans to focus on profitable growth and maintaining a strong balance sheet amid ongoing macroeconomic challenges [5][20]

Core Viewpoint - Cryoport, Inc. will report its financial results for the third quarter of 2024 on November 7, 2024, after U.S. markets close [1]. Financial Results Announcement - The earnings release will be accompanied by a document titled "Cryoport Third Quarter 2024 in Review," which will provide a review of the company's financial and operational performance [2]. - The document will be available at 4:05 p.m. ET on the same day, designed for pre-reading before the Q&A conference call [2]. Conference Call Details - A conference call will be held on November 7, 2024, at 5:00 p.m. ET, formatted as a Q&A session for the investment community [3]. - Dial-in numbers for the call are provided for both U.S. and international participants, along with a confirmation code [4]. Replay Information - The Q&A call will be recorded and available for replay approximately three hours after the live event, accessible on the company's Investor Relations website [5]. - A dial-in replay will also be available until November 14, 2024, with specific numbers provided for access [5]. Company Overview - Cryoport, Inc. is a global leader in supply chain solutions for the life sciences, focusing on cell and gene therapies [6]. - The company offers a wide range of services, including advanced temperature-controlled packaging, bio-logistics, and cryogenic systems, aimed at reducing risks and ensuring certainty for its clients [6]. - The corporate headquarters is located in Nashville, Tennessee, with over 50 global locations across 17 countries [7].

Core Insights - Cryoport, Inc. has formed a strategic alliance with Gulf Coast Regional Blood Center to enhance the availability of cryopreserved allogeneic leukopaks for cellular therapy research and treatment [1][2] - The partnership coincides with the opening of Cryoport's new IntegriCell™ facility in Houston, Texas, which is designed to support the life sciences community [1][2] Company Overview - Cryoport, Inc. is a global leader in supply chain solutions for the life sciences, focusing on cell and gene therapies, providing a range of services including temperature-controlled packaging and bio-logistics [3][4] - Gulf Coast Regional Blood Center is one of the largest community blood centers in the U.S., serving 170 hospitals and conducting over 7,000 mobile blood drives annually [5] Partnership Details - The collaboration integrates GCRBC's Cellular Life Solutions program with Cryoport's cryopreservation expertise, creating a unified service offering for the life sciences sector [2] - The proximity of GCRBC's CLS program to Cryoport's facility allows for efficient local transport of leukopaks, enhancing the quality and consistency of cellular therapy products [2] Strategic Importance - This partnership aims to accelerate the development of life-saving treatments by providing a streamlined process for cellular therapy products [2] - The alliance is expected to expand Cryoport's reach and impact in the cryopreservation services market, addressing industry challenges in the delivery of critical cellular materials [2]

Two ISO-Certified Industry Leaders Collaborate to Provide Fertility Clinics with Complete, Trusted Solutions for Secure IVF Specimen Management and Transport NASHVILLE, Tenn. and NEW YORK, Oct. 21, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences industry, and TMRW Life Sciences ("TMRW"), a fertility technology company offering the highest standard of care in offsite storage for frozen eggs, embryos and sperm in the U.S. with th ...

Partnership Will Enhance Support for Biopharmaceutical Companies in Developing Cell and Gene Therapies and mRNA-Based Treatments NASHVILLE, Tenn. and CONROE, Texas, Oct. 15, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences, and VGXI, Inc., (VXGI) a subsidiary of GeneOne Life Science Inc. ("GeneOne" KOSPI: 011000) today announced a strategic partnership to support biopharmaceutical companies in developing cell and gene therapies ...

The IntegriCell Platform Will Deliver High-Quality Cryopreservation Services for Cell-Based Therapies NASHVILLE, Tenn., Oct. 7, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in supply chain solutions for the life sciences, today announced the launch of its IntegriCell™ cryopreservation services solution provided by Cryoport Systems with the opening of its new facility located at Cryoport's integrated supply chain campus in Houston, Texas. This new state-of ...

NASHVILLE, Tenn. and RANCHO CORDOVA, Calif., Sept. 25, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in supply chain solutions for the life sciences industry, and SK pharmteco, a global contract development and manufacturing organization, today announced a strategic collaboration to provide fully integrated logistics and manufacturing services to biotechnology and pharmaceutical companies. Cryoport, with its ability to provide end-to-end cell and gene therapy support servi ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-34632 CRYOPORT, I ...

Cryoport, Inc. (NASDAQ:CYRX) Q2 2024 Results Conference Call August 6, 2024 5:00 PM ET Company Participants Todd Fromer - Investor Relations-KCSA Strategic Communications Jerrell Shelton - Chief Executive Officer Mark Sawicki - Chief Scientific Officer Robert Stefanovich - Chief Financial Officer Conference Call Participants Paul Knight - KeyBanc David Larsen - BTIG Philip Song - Leerink Partners Matt Stanton - Jefferies Yuan Zhi - B. Riley David Saxon - Needham Operator [Abrupt Start] Cryoport Second Quart ...

CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.42 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 10.81%. A quarter ago, it was expected that this company would post a loss of $0.37 per share when it actually produced a loss of $0.43, delivering a surprise of -16.22%. Over the last four quarters, the company has surpass ...